BMJ· 2020Q1
Treatment of epithelial ovarian cancer
- 924citations
- Q1SCImago
- 2020year
Short summary
Genetic testing for gene mutations affecting treatment is now standard for all women with epithelial ovarian cancer, alongside integrated care teams and surgical cytoreduction to R0 followed by adjuvant chemotherapy.
AI-generated from the title and abstract; the full text is not read.
Key points
- Integrated care teams are crucial for managing epithelial ovarian cancer.
- Surgical cytoreduction to R0 is the primary treatment modality.
- Adjuvant chemotherapy follows surgical cytoreduction.
- Genetic testing for gene mutations impacting treatment is standard for all patients.
- Maintenance therapies (PARP inhibitors, bevacizumab, immunotherapy) are increasingly used for recurrent disease.
AI-generated from the title and abstract; the full text is not read.
Abstract
Ovarian cancer is the third most common gynecologic malignancy worldwide but accounts for the highest mortality rate among these cancers. A stepwise approach to assessment, diagnosis, and treatment is vital to appropriate management of this disease process. An integrated approach with gynecologic oncologists as well as medical oncologists, pathologists, and radiologists is of paramount importance to improving outcomes. Surgical cytoreduction to R0 is the mainstay of treatment, followed by adjuvant chemotherapy. Genetic testing for gene mutations that affect treatment is the standard of care for all women with epithelial ovarian cancer. Nearly all women will have a recurrence, and the treatment of recurrent ovarian cancer continues to be nuanced and requires extensive review of up to date modalities that balance efficacy with the patient's quality of life. Maintenance therapy with poly ADP-ribose polymerase inhibitors, bevacizumab, and/or drugs targeting homologous recombination deficiency is becoming more widely used in the treatment of ovarian cancer, and the advancement of immunotherapy is further revolutionizing treatment targets.
The authors' abstract, as published at the source. BMJ, 2020 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Reproductive Medicine
Reproductive MedicineMedicine